MEDINDIA
English
हिन्दी
Español
français
中文
ReachMD XM 157, the first and only network for medical professionals, willair the program "AVP Antagonists: Turning the Tide Against Hyponatremia" fourtimes a day October 27-31, November 10-14, and January 5-8. Healthcareprofessionals can tune in to XM Satellite Radio Channel 157 or listen OnDemandat http://www.ReachMD.com/AVP1. Use promo code VaprisolPR to listen and toreceive a free 6-month membership to ReachMD.com.
The program features interviews with Joseph Verbalis, MD, Professor ofMedicine and Physiology at Georgetown University Medical Center and ScottBeegle, MD, Assistant Professor of Medicine at Albany Medical College.Program host Lee Freedman, MD, Internal Medicine, Northwestern MemorialHospital, Evanston Northwestern Healthcare: Evanston Hospital, Highland ParkHospital, and Glenbrook Hospital will interview Dr. Verbalis and Dr. Beegle.The topics include:
"AVP Antagonists: Turning the Tide Against Hyponatremia" is sponsored byAstellas Pharma US, Inc. in support of VAPRISOL(R) (conivaptan hydrochlorideinjection), a nonpeptide dual AVP antagonist indicated for the treatment ofeuvolemic and hypervolemic hyponatremia in hospitalized patients.
Gary Epstein, CEO of ReachMD said, "We're excited to work with Astellas tobroadcast this very special program. Our programming continues to diversifywhich helps all types of physicians gain the latest information aboutdisorders and new approaches of treatment relevant to them."
About Vaprisol: Discovered and developed by Astellas Pharma Inc.headquartered in Tokyo, Japan, Vaprisol is a drug that blocks the activity ofAVP, resulting in increased urine output without loss of valuable electrolytessuch as sodium and potassium. This effect, known as "aquaresis," helps toincrease serum sodium levels in patients with hyponatremia. Vaprisol is thefirst AVP receptor antagonist with a demonstrated safety profile and thateffectively promotes aquaresis in order to help restore salt and water balancein patients with euvolemic and hypervolemic hyponatremia.
Vaprisol is indicated for the treatment of euvolemic and hypervolemichyponatremia in hospitalized patients. Vaprisol is not indicated for thetreatment of congestive heart failure. It should only be used for thetreatment of hyponatremia in patients with underlying heart failure when theexpected benefit of raising serum sodium outweighs the increased risk ofadverse events. Vaprisol is contraindicated in patients with hypovolemichyponatremia. In addition, coadministration of Vaprisol with potent CYP3A4inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritanovir, andindinavir, is contraindicated. Serum sodium, volume, and neurological statusmust be monitored frequently because Vaprisol potentially can cause overlyrapid correction of sodium leading to serious sequelae. The use of Vaprisol inpatients with hepatic impairment (including ascites, cirrhosis, or portalhypertension) or renal impairment has not been systematically evaluated. Usecaution when administering Vaprisol to these patients. The most common adversereactions reported were infusion site reactions (incidence of 73% and 63% for20 mg/day and 40 mg/day respectively) which were also the most common type ofadverse reaction leading to discontinuation of Vaprisol. Discontinuations fromtreatment due to infusion site reactions were more common amongVaprisol-treated patients (3%) than among placebo-treated patients (0%). Othercommon adverse reactions were headaches (8%, 10%), hypokalemia (22%, 10%),orthostatic hypotension (14%, 6%), and pyrexia (11%, 5%) for Vaprisol 20mg/dayand 40mg/day, respectively. For more information about Vaprisol or fullprescribing information, please visit http://www.vaprisol.com.
About Astellas: Astellas Pharma US, Inc., located in Deerfield, Illinois,is a US affiliate of Tokyo-based Astellas Pharma Inc., Astellas is apharmaceutical company dedicated to improving the health of people around theworld through the provision of innovative and reliable pharmaceuticalproducts. The organization is committed to becoming a global pharmaceuticalcompany by combining outstanding R&D and marketing capabilities and continuingto grow in the world pharmaceutical market. For more information aboutAstellas Pharma US, Inc., please visit http://www.astellas.com/us.
About ReachMD XM 157: A leading provider of advanced healthcareinformation and education for medical professionals, ReachMD provides the mostup to date healthcare information in the field through satellite radio, mobilephone, and online programs. These convenient and accessible technologiesdeliver the latest information in best practices and new advances in treatmentto healthcare professionals. For more information, visithttp://www.ReachMD.com.-- Hyponatremia incidence, causes, and consequences -- Diagnostic algorithm and general treatment principles -- AVP antagonists rationale for treatment -- VAPRISOL(R) efficacy, safety and dosing information
SOURCE ReachMD XM 157
